(S)-3-(4-methoxybenzyl)morpholine | 1251751-08-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (S)-3-(4-methoxybenzyl)morpholine
• 英文别名: Morpholine, 3-[(4-methoxyphenyl)methyl]-, (3S)-；(3S)-3-[(4-methoxyphenyl)methyl]morpholine
• CAS: 1251751-08-2
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: GUEULQXXZJJPGH-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-3-(4-methoxybenzyl)morpholine 在 三溴化硼 、 sodium hydride 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 48.5h， 生成 tert-butyl (3S)-3-(4-((2,6-dioxopiperidin-3-yl)oxy)benzyl)morpholine-4-carboxylate
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS
  [FR] COMPOSÉS POUR LE CIBLAGE DE LA DÉGRADATION DE PROTÉINES IRAK4

  摘要：

  This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

  公开号：

  WO2023283610A1
• 作为产物：
  描述：

  4-甲氧基-L-苯丙氨酸 在 lithium aluminium tetrahydride 、 硼烷四氢呋喃络合物 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 32.0h， 生成 (S)-3-(4-methoxybenzyl)morpholine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS
  [FR] COMPOSÉS POUR LE CIBLAGE DE LA DÉGRADATION DE PROTÉINES IRAK4

  摘要：

  This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.

  公开号：

  WO2023283610A1

文献信息

• Synthesis of Enantiopure 3-Substituted Morpholines
  作者：Jan Bornholdt、Jakob Felding、Jesper Langgaard Kristensen

  DOI：10.1021/jo101339g

  日期：2010.11.5

  Enantiopure 3-substituted morpholines were assembled through ring-opening of a N-2-benzothiazolesulfonyl (Bts) activated aziridine with organocuprates followed by a ring annulation reaction with a vinylsulfonium salt under microwave conditions. Deprotection of the N-Bts group proceeds under very mild conditions with 2-mercaptoacetic acid and LiOH at rt.
• [EN] COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS<br/>[FR] COMPOSÉS POUR LE CIBLAGE DE LA DÉGRADATION DE PROTÉINES IRAK4
  申请人：[en]BIOGEN MA INC.

  公开号：WO2023283610A1

  公开（公告）日：2023-01-12

  This disclosure relates to compounds of Formula (A): IRAK—L—DSM (A), or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches IRAK to DSM; and IRAK is an IRAK4 binding moiety represented by Formula (I) that is covalently attached to linker L; in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of IRAK4 proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of IRAK4 proteins. The present disclosure also provides methods of treating disorders responsive to modulation of IRAK4 activity and/or degradation of IRAK4 with at least one compound described herein.